The Nasdaq Biotechnology Index rose by more than 2.4%. Among them, Editas Medicine increased by 34.72%, Arcturus Therapeutics Holdings Inc. rose by 29.01%, and Stoke Therapeutics climbed by 24.98%. In contrast, Pliant fell by 6.25%, Autolus Therapeutics dropped by 14.62%, and Zevra Therapeutics decreased by 19.81%

The Nasdaq Biotechnology Index closed up more than 2.4%, with constituent stock Editas Medicine rising 34.72%, Arcturus Therapeutics Holdings Inc. up 29.01%, and Stoke Therapeutics up 24.98%, ranking third in performance. Pliant, on the other hand, fell 6.25%, ranking third in decline, while Autolus Therapeutics dropped 14.62% and Zevra Therapeutics fell 19.81%